DREAMM-7: a phase III study of the efficacy and safety of belantamab mafodotin (belamaf) with Bortezomib, and dexamethasone (B-Vd) in patients with relapsed/refractory multiple myeloma (RRMM)
DREAMM-7: a phase III study of the efficacy and safety of belantamab mafodotin (belamaf) with Bortezomib, and dexamethasone (B-Vd) in patients with relapsed/refractory multiple myeloma (RRMM)
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Δεν υπάρχει περίληψη
Έτος δημοσίευσης:
2020
Συγγραφείς:
Rifkin, Robert M Boyd, Kevin Grosicki, Sebastian Kim, Kihyun Di Raimondo, Francesco Dimopoulos, Meletios A Weisel, Katja Arnulf, Bertrand Hajek, Roman Hungria, Vania others
